BR112022019892A2 - Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo - Google Patents
Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduoInfo
- Publication number
- BR112022019892A2 BR112022019892A2 BR112022019892A BR112022019892A BR112022019892A2 BR 112022019892 A2 BR112022019892 A2 BR 112022019892A2 BR 112022019892 A BR112022019892 A BR 112022019892A BR 112022019892 A BR112022019892 A BR 112022019892A BR 112022019892 A2 BR112022019892 A2 BR 112022019892A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- delaying
- progression
- injury
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005130P | 2020-04-03 | 2020-04-03 | |
| US202063079810P | 2020-09-17 | 2020-09-17 | |
| PCT/US2021/025626 WO2021203030A2 (en) | 2020-04-03 | 2021-04-02 | Methods of use of anti-trem2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019892A2 true BR112022019892A2 (pt) | 2022-12-13 |
Family
ID=75674977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019892A BR112022019892A2 (pt) | 2020-04-03 | 2021-04-02 | Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230183341A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126953A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520516A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005848A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667308A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021247286A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019892A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3172451A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296992A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012182A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021203030A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062436T2 (hu) * | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| CN115003699A (zh) * | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| IL308804A (en) * | 2021-05-28 | 2024-01-01 | Vigil Neuroscience Inc | TREM2 agonistic biomarkers and methods of using them |
| JP2024525559A (ja) * | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| MX2024010324A (es) * | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499695A1 (en) * | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| CN117624360A (zh) | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2026062585A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
| WO2026062582A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7105825B2 (en) * | 1999-04-14 | 2006-09-12 | Juni Jack E | Single photon emission computed tomography system |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| EA201790342A1 (ru) * | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| CN106465199B (zh) * | 2014-09-26 | 2019-12-13 | 太阳专利信托公司 | 设备到设备无线通信方法和用户设备 |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| US11058720B2 (en) * | 2016-05-20 | 2021-07-13 | Cedars-Sinai Medical Center | Methods of treating or preventing alzheimer's disease and associated conditions |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | Trem2切断モジュレーター及びその使用 |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| HUE062436T2 (hu) * | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CN115003699A (zh) * | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| CN115768794A (zh) * | 2020-02-24 | 2023-03-07 | 艾利妥 | 抗trem2抗体的使用方法 |
| MX2024010324A (es) * | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
-
2021
- 2021-04-02 CA CA3172451A patent/CA3172451A1/en active Pending
- 2021-04-02 IL IL296992A patent/IL296992A/en unknown
- 2021-04-02 KR KR1020227038069A patent/KR20230005848A/ko active Pending
- 2021-04-02 JP JP2022560204A patent/JP2023520516A/ja active Pending
- 2021-04-02 AU AU2021247286A patent/AU2021247286A1/en active Pending
- 2021-04-02 BR BR112022019892A patent/BR112022019892A2/pt not_active IP Right Cessation
- 2021-04-02 MX MX2022012182A patent/MX2022012182A/es unknown
- 2021-04-02 EP EP21721714.0A patent/EP4126953A2/en active Pending
- 2021-04-02 CN CN202180037525.0A patent/CN115667308A/zh active Pending
- 2021-04-02 WO PCT/US2021/025626 patent/WO2021203030A2/en not_active Ceased
- 2021-04-02 US US17/916,728 patent/US20230183341A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL296992A (en) | 2022-12-01 |
| WO2021203030A3 (en) | 2021-11-18 |
| AU2021247286A1 (en) | 2022-10-20 |
| KR20230005848A (ko) | 2023-01-10 |
| CN115667308A (zh) | 2023-01-31 |
| CA3172451A1 (en) | 2021-10-07 |
| WO2021203030A2 (en) | 2021-10-07 |
| JP2023520516A (ja) | 2023-05-17 |
| EP4126953A2 (en) | 2023-02-08 |
| US20230183341A1 (en) | 2023-06-15 |
| MX2022012182A (es) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| MX2022012182A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
| EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
| MX2024010324A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| BR112022011337A2 (pt) | Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
| BR112023025188A2 (pt) | Métodos de uso de anticorpos anti-sortilina | |
| AR122237A1 (es) | Anticuerpos anti-sortilina y métodos para su uso | |
| EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2873 DE 27-01-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |